Nebivolol Amarox

Nebivolol, the active ingredient in Nebivolol Amarox, is a beta blocker presented as a tablet for oral use. It selectively blocks β1‑adrenergic receptors and promotes nitric‑oxide mediated vasodilation, helping to lower high blood pressure and improve outcomes in patients with chronic heart failure.

GNH USA supplies Nebivolol Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, ensuring quality and regulatory compliance across global markets.

Nebivolol is indicated for cardiovascular conditions that involve elevated blood pressure or impaired cardiac function.

- Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. - Chronic heart failure: improves left‑ventricular ejection fraction and reduces hospitalization risk. - Elevated heart rate associated with hypertension: helps control resting heart rate while managing blood pressure.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Fatigue: general tiredness or reduced energy levels. - Nausea: upset stomach or urge to vomit. - Bradycardia: slower than normal heart rate. - Nasal congestion: feeling of blocked nose.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: dangerously low blood pressure causing faintness. - Heart block: impaired electrical conduction in the heart. - Bronchospasm: narrowing of airways, especially in patients with asthma. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Liver enzyme elevation: abnormal liver function tests.

Before initiating Nebivolol therapy, certain precautions should be considered.

- Blood pressure monitoring: regularly check to avoid excessive hypotension. - Cardiac assessment: evaluate heart rate and rhythm, especially in patients with conduction disorders. - Concomitant beta‑blockers: avoid combining with other β‑blockers to prevent additive effects. - Respiratory conditions: use caution in patients with asthma or chronic obstructive pulmonary disease. - Renal impairment: dose adjustment may be needed in severe kidney dysfunction. - Store at room temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic and inotropic effects. - Non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): may cause severe bradycardia or heart block. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive effect. - ACE inhibitors or ARBs: combined use can lead to excessive blood pressure reduction. - NSAIDs: may attenuate antihypertensive efficacy. - Digoxin: monitor for bradycardia. - Antiarrhythmic agents (e.g., amiodarone): observe for conduction abnormalities.